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Abstract
64Cu radiolabelled nanodiscs based on the 11 α-helix MSP1E3D1 protein and 1-palmitoyl-
2-oleoyl-sn-glycero-3-phosphatidylcholine lipids were, for the first time, followed in vivo by
positron emission tomography for evaluating the biodistribution of nanodiscs. A cancer
tumor bearing mouse model was used for the investigations, and it was found that the
approximately 13 nm nanodiscs, due to their size, permeate deeply into cancer tissue. This
makes them promising candidates for both drug delivery purposes and as advanced imag-
ing agents. For the radiolabelling, a simple approach for 64Cu radiolabelling of proteins via a
chelating agent, DOTA, was developed. The reaction was performed at sufficiently mild
conditions to be compatible with labelling of the protein part of a lipid-protein particle while
fully conserving the particle structure including the amphipathic protein fold.
Introduction
Nanoparticle-based drug delivery systems are widely investigated with the aim of improving
the pharmacological properties of conventional drugs and to solve problems with low solubility
and poor biodistribution [1]. A central focus area lies in cancer treatment and diagnosis, where
the ability of nanoparticles to accumulate in tumor tissues through the enhanced permeability
and retention (EPR) effect is pursued [2, 3]. In this context, nanoparticles are used as drug
delivery vehicles as well as imaging agents in cancer diagnosis and treatment selection, provid-
ing direct visualization of the general biodistribution and degree of tumor accumulation of
nanoparticle-based anti-cancer drugs [4, 5].
Nanodiscs, engineered from human high density lipoprotein, are disc-shaped phospholipid
bilayers stabilized by two surrounding α-helical amphipathic membrane scaffold proteins
(MSPs). The MSPs keep the nanodiscs in their well-defined shape and size over a wide range of
conditions including concentrations and temperatures [6–8]. The nanodisc system has been
designed and optimized to be a platform for studying membrane proteins [9, 10]. In these
applications, the phospholipid bilayer offers a perfect environment for membrane proteins and
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stabilize their natural conformation and function in a more native like state than more com-
monly used detergent-based systems [11]. Nanodiscs have shown promising results for drug
delivery usage in for example the delivery of an influenza vaccine, as studies have shown them
able to trigger a broad protective immune response in mice [12] and for a specific antigen
which has shown a therapeutic potential regarding the autoimmune disease myasthenia gravis
[13]. However, the full potential of the nanodiscs in this type of applications has not yet been
elucidated as information regarding their biodistribution is sparse and still incomplete [14].
The present article presents, for the first time, a combined positron emission tomography
(PET) and computed tomography (CT) real-time, non-invasive visualization of the nanodisc
biodistribution in vivo including visualization of its permeation into cancer tumor tissue in a
tumor bearing mouse model.
To reach this goal, a simple method for 64Cu radiolabelling was developed allowing for conju-
gating the protein component of the nanodisc with the chelating agent 1,4,7,10-tetraazacyclodo-
decane-1,4,7,10-tetraacetic acid (DOTA). This enabled binding of the radioactive isotope 64Cu
(Fig 1) while at the same time involving minimal modifications of the biomolecule in order to
avoid significant structural changes. An alternative DOTA-based approach has recently been
proposed for the labeling of the 12 amino acid QFP peptide [15]. For the present work, we have
developed a milder reaction approach that is compatible with proteins in solution and allow for
labeling of the MSP, while conserving their amphipathic fold and ability to form nanodiscs.
Therefore, the method is applicable to other protein systems. 64Cu was chosen as the radionuclide
because of its relatively long half-life (12.7 hours) and relatively low maximum positron energy
(0.66 MeV), which makes it very suitable for PET imaging. Nanodiscs were assembled with
DOTA-conjugated MSPs and structurally characterized by combined small-angle x-ray scatter-
ing (SAXS) and small angle neutron scattering (SANS) confirming that the nanodisc structure
indeed remained fully intact after DOTA-conjugation. The DOTA-conjugated nanodiscs were
Fig 1. Schematics of nanodisc radiolabelling. A: chemical reaction of DOTA-NHS ester-conjugation to MSP lysines and further radiolabelling with 64Cu2+.
B: symbol explanation for C. C 1: MD simulation of ordinary nanodisc[6] (lipids in blue, MSP in red). 2: nanodisc assembled with DOTA conjugated MSP. 3:
64Cu radiolabelled nanodisc.
doi:10.1371/journal.pone.0129310.g001
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radioactively labeled with 64Cu and their in vitro stability evaluated in mouse blood plasma,
showing that the 64Cu-labeled nanodiscs were sufficiently stable over time to be relevant for in
vivo studies. Finally, 64Cu-labelled nanodiscs were intravenously administered to 10 tumor bear-
ing nude mice and the biodistribution analyzed by PET and gamma counting of tissues of inter-
est. This showed that the nanodiscs accumulate intensively in the tumor tissue as well as in the
kidneys.
Materials and Methods
Materials
DOTA-NHS-ester was purchased from Macrocyclic, Dallas, Texas, USA. POPC was purchased
from Avanti Polar Lipids, Alabaster, Alabama, USA. Sodium Cholate, Sodium Phosphate,
NaCl and Dulbecco’s PBS were purchased from Sigma-Aldrich, St. Louis, Missouri, USA.
Ammonium acetate was purchased fromMerck, Damstadt, Germany. 64CuCl2 was obtained
from the Hevesy Laboratory Risø DTU, Roskilde, Denmark.
DOTA-conjugation of MSP
MSP1E3D1(-) (MSP) was expressed and purified as previously described [16]. 1, 3 or 5 molar
equivalents 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid mono (N-Hydroxysucci-
nimide ester) (DOTA) to number of lysines fromMSP were dissolved in sodium phosphate
buffer (0.1 M NaPO4, 0.1 M NaCl, pH 8) containing MSP1E3D1(-) (4.7 mg/ml) and left for
continuous stirring for 1 hour at 4°C. DOTA-conjugation was confirmed and analysed by
MALDI TOF on a Microflex (Bruker, Billerica, MA, USA) and a Q-Tof Ultimate (Micromass,
Beverly, MA, USA) using a HCCA matrix (Bruker, Billerica, MA, USA).
Assembly and purification of nanodiscs
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine (POPC) (20 mg/ml) in a chloroform
stock solution was transferred to a glass vial. The chloroform was evaporated using a flow of
nitrogen gas for 1 hour. Excessive chloroform was removed using a rotary evaporator over-
night. Dry POPC was dissolved in cholate buffer (0.1 M NaPO4, 0.1 M NaCl, 20 mM sodium
cholate, pH 8) to a concentration of 0.05 M. MSP-DOTA in a sodium phosphate buffer (0.1 M
NaPO4, 0.1 M NaCl, pH 8) was mixed with POPC solubilized in cholate-containing buffer (0.1
M NaPO4, 0.1 M NaCl, 20 mM sodium cholate, pH 8) in a molar ratio of 130:1 POPC:MSP
and left for continuous shaking for 90 min at 4°C. 0.5 ml Biobeads (BioRad, Hercules, CA,
USA) to 1 ml sample was added to the mixture, which was left for continuous shaking over
night at 4°C. The Biobeads were removed by centrifugation for 1 min. at 4000 RPM and filtra-
tion through a 0.22 μm syringe filter. DOTA-conjugated nanodiscs were purified by size exclu-
sion chromatography (SEC) using a Superdex 200 column (10/300) (GE healthcare, Little
Chalfont, UK) with a 0.5 ml/min flow using ammonium acetate buffer (0.1 M CH3CO2NH4,
0.1 M NaCl, pH 7.5) as eluent.
64Cu labelling and purification
1 ml nanodisc solution (approximately 12.8 mg/ml DOTA conjugated nanodiscs) in ammo-
nium acetate buffer (0.1 M CH3CO2NH4, 0.1 M NaCl, pH 7.5) was added to a dry vial contain-
ing 587.2 MBq 64CuCl2 and reacted for 45 min at room temperature. The 1 ml solution was
purified and analyzed by SEC using a Superdex 200 column (10/300) (GE healthcare, Little
Chalfont, UK) with phosphate buffer saline (PBS) as eluent. A flow rate of 0.5 ml/min was
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applied and, 64Cu labelled nanodiscs were detected by UV280 nm and radioactivity by gamma
detection using a NaI gamma detector (Bicron, Canaan, CT, USA).
Structural characterization by SAXS and SANS
SAXS data were obtained at the BioSAXS instrument formerly at beamline ID14-3 at European
Synchrotron Radiation Facility (ESRF) in Grenoble[17]. SANS data were obtained at the D11
SANS instrument at ILL[18]. For small-angle X-ray scattering, 50 μl samples of DOTA-conju-
gated (5.3 mg/ml) and unconjugated nanodiscs (4.2 mg/ml) in Tris buffer (20 mM Tris, 0.1 M
NaCl, pH 7.5) and the Tris buffer backgrounds were measured at 20°C by slow flow through
the X-ray beam in a capillary cuvette. The obtained data were azimuthally averaged and buffer
background measurements were subtracted from sample measurements. The data were con-
verted to absolute scale (i.e. intensities in units of cm/cm3) using BSA as a secondary standard.
The data analysis was carried out on these background subtracted, absolute scaled scattering
intensity data, I(q). Prior to the small-angle neutron scattering experiments, the buffers of the
two samples were exchanged to a D2O based Tris buffer (20 mM Tris, 0.1 M NaCl, pH 7.5)
using centrifugation spin filters. The SANS measurements were performed in 2mm rectangular
Hellma Quartz cuvettes at 20°C. A neutron wavelength of 6Å and sample to detector distances
of, respectively, 1.5 m and 10.5 m were used in order to cover the desired q-range. Samples
were exposed for 6 minutes at the 1.5 m setting and 15 minutes at the 10.5 m setting. Azimuth-
ally averaged, background subtracted data were absolute scale calibrated using H2O as a sec-
ondary standard. Further data analysis was carried out on these background subtracted,
absolute scaled scattering intensity data, I(q).
In vitro stability
64Cu-nanodiscs were prepared as described earlier. 0.5 mg 64Cu-nanodiscs in solution (2.75
mg/ml) with an activity of 6.2 MBq were incubated at 37°C in 1 ml 0.22μl filtered mouse
plasma harvested from BomTac:NMRI-Foxn1nu nude mice and analyzed after 1, 12, 24 and 48
hours of incubation. The nanodiscs in plasma were analyzed by SEC using a BioSep-SEC-
s2000 column with PBS buffer as eluent. A flow rate of 0.5 ml/min was applied. Eluate was
detected by gamma detection using a NaI gamma detector (Bicron, Canaan, CT, USA).
Animal models
Human lung carcinoid (NCI-H727) tumor cells (~107), purchased from European Collection
of Cell Cultures (ECACC, Porton Down, UK) were inoculated in the left and right flank of
BomTac:NMRI-Foxn1nu nude mice (n = 10) in a 200 μl volume with a 1:1 mixture of sus-
pended cells and Matrigel (BD Biosciences, San Jose, CA, USA). Tumors were allowed to grow
for three weeks before scanning to ensure exponential tumor growth. Mice were fed with 1314
TPF (Altromin, Lage, Germany) and water ad libitum. All experiments involving animals were
approved by the national authority. A computer tomography (CT) scan was acquired prior to
the PET scan for anatomical localization of foci on a MicroCAT II system (Siemens Medical
Solutions, Malvern, PA, USA). CT settings were a tube voltage of 61 kVp, a tube current of
500 μA, 360 rotation steps, an exposure time of 440 ms and a voxel size of 0.092 mm.
Micro-PET/CT imaging
The mice were anaesthetized using 4% sevofluran (Abbott Scandinavia AB, Solna, Sweden)
mixed with 35% O2 in N2 before injected intravenously with 10 MBq of
64Cu-labeled nanodiscs
in a lateral tail vein. General anaesthesia was maintained using 2.5% sevofluran (Abbott
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Scandinavia AB, Solna, Sweden) mixed with 35% O2 in N2. Static PET scans were acquired, 1,
12, 24 and 48 hours post-injection on a dedicated small animal PET scanner (MicroPET Focus
120, Siemens Medical Solutions, Malvern, PA, USA). Acquisition times were 10, 15, 20 and 30
minutes for the 1, 12, 24 and 48 hour scans, respectively, to ensure proper signal-to-noise
ratios. The voxel size was 0.866 x 0.866 x 0.796 mm3, and the resolution was 1.4 mm in the cen-
tre-field-of-view. Data were reconstructed with the maximum a posterior (MAP) reconstruc-
tion algorithm.
All animal care and experimental procedures were approved by the Danish Animal Welfare
Council (Permit number: 2013–15–2934–00064).
Quantitative analysis of PET images
PET and CT images were analysed as fused images using the Inveon software (Siemens).
Regions of interest (ROIs) were drawn around liver, kidney, spleen, muscle, tumors and the
left-ventricle. Uptake in the left ventricle of the heart was taking as a measure of the blood con-
centration. Percentage of injected dose per gram (%ID/g) was calculated.
Gamma counting
Following the 48 hour PET scan, the mice were killed, blood collected and organs of interest
harvested for endpoint measurements in a Wizard2 gamma-counter (Perkin Elmer, Skovlunde,
Denmark) with a counting efficiency of 9.43% for 64Cu. Percentage injected dose per gram
(%ID/g) and tumor-to-muscle ratios were calculated.
Statistical analysis
Student t-test was applied for two-group comparisons and comparison of three or more groups
was done using One-way ANOVA with Bonferroni-corrected post hoc test. PET and gamma
counting results are reported as mean ±.SEM. Statistical analysis was performed using Graph-
Pad Prism 5 software (GraphPad Software, Inc.). A p-value of 0.05 was considered significant.
Results and Discussion
DOTA-conjugation of MSP
The metal chelating reagent DOTA-NHS-ester (DOTA) was reacted onto lysine groups of the
MSP, which was confirmed by MALDI TOF analysis (Fig A in S1 File). The reaction was car-
ried out at physiological conditions in order to conserve the MSP. DOTA was chosen as the
chelate, as it has been widely used in radiopharmaceuticals and is well characterized through-
out the literature [19]. DOTA reacted satisfactory with MSP, and a molar ratio of 5:1 DOTA:
lysines was found to be a suitable reaction condition, which resulted in a rough average of 5
DOTA bound to 1 MSP. This was believed to be an appropriate amount of chelate for the Cu-
64 reaction, while at the same time it was not expected to affect the protein properties of MSP
nor the nanodisc reconstitution.
Assembly, size and structure of DOTA-conjugated nanodiscs
The nanodiscs were assembled with DOTA-conjugated MSP and POPC before radiolabelling
with 64Cu. DOTA-modified nanodiscs exhibited the same reconstitution behavior as unmodi-
fied nanodiscs as judged from size exclusion chromatography (SEC) data from the purification
process, and in both cases evidence of well-defined discs was observed (Fig B in S1 File). SEC is
a low-resolution technique and in order to obtain higher resolution structural evidence that the
DOTA-conjugated nanodiscs had the same structure as the unmodified nanodiscs, a small-
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angle scattering study was performed. The obtained scattering data and the derived pair-dis-
tance distribution functions, p(r), from DOTA conjugated and ordinary nanodiscs (Fig 2) were
very similar and in accordance with previous observations from a smaller version of the discs
[20]. The p(r)-functions show that unmodified and DOTA-nanodiscs have a diameter of
approximately 130 Å. However, a small difference between the two is seen in the interval from
60 to 130 Å where the p(r)-functions of DOTA-modified nanodiscs are shifted towards larger
distances. A model accounting for a slight anisotropy in the shape of the discs was generalized
from a previous study [21] and fitted to the experimental data (see model and fits in Fig 2). In
accordance with previous findings, each nanodisc was stabilized by two MSPs. From the fits,
the following parameters describing the scattering from the unlabeled discs were obtained: The
membrane scaffolding protein belt was refined to a thickness of 9.8 Å, the area per lipid head-
group was refined to 70.3 Å2, which is slightly above previously reported value of 62.7 Å2
observed in large bilayer membranes [22]; the partial specific molecular volume of MSP was
inferred to be 37900 Å3 and similarly, the partial specific molecular volume of POPC was esti-
mated to be 1280 Å3. From these parameters, one can derive that the number-weighted average
number of POPC molecules per disc to be 188. For the DOTA-conjugated discs, we obtained a
value of 8.9 Å for the thickness of the membrane scaffolding protein belt and a value of 61.6 Å2
Fig 2. SAXS and SANS data of unmodified and DOTA conjugated nanodiscs. Top left plot: SANS data of unmodified nanodiscs (in red) and DOT-
conjungated nanodiscs (in blue) with their respective fits. Top right plot: SAXS data of unmodified nanodiscs (in red) and DOTA-conjugated nanodiscs (in
blue) with their respective fits. Bottom left plot: Pair-distance distribution functions, p(r), refined from the obtained SANS data of unmodified nanodiscs (in red)
and DOTA-conjugated nanodiscs (in blue). Bottom right plot: p(r)-distributions refined from the obtained SAXS data of unmodified nanodiscs (in red) and
DOTA-conjugated nanodiscs (in blue). To the right, a rendering of the refined structure is shown.
doi:10.1371/journal.pone.0129310.g002
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for the area per lipid headgroup. The partial specific molecular volumes of MSP and POPC
were refined to very similar values as for the unlabeled discs: 36800 Å3 and 1280 Å3, respec-
tively. These parameters result in a number-weighted average number of lipids per disc of 247.
Thus, from the analysis of the small-angle scattering data, we conclude that the overall disc-
shape is fairly unaffected by the DOTA-conjugation. However, the conjugation does seem to
introduce minor perturbations in the fine-structure of the particles.
64Cu-labelling of nanodiscs
DOTA-modified nanodiscs were 64Cu-labelled by simple incubation with 64CuCl2 in a pH 7.5
ammonium acetate buffer at room temperature. The labelling was confirmed by SEC with dual
detection of UV 280 nm and gamma-emission, which clearly showed that 64Cu was bound to
the nanodisc fraction (Fig 3). The finding of efficient radiolabelling at these mild conditions
was very satisfactory, as previous work reports the requirement for more harsh reaction condi-
tions at lower pH [23–26], which is generally not compatible with the conservation of the struc-
ture and function of protein-based biomolecules.
The in vitro labelling stability of the nanodiscs was investigated prior to the in vivo biodistri-
bution studies to examine to which extent an observed distribution could be assigned to nano-
discs and not only to degradation products or unbound CuCl2. For this study, the nanodiscs
were incubated in mouse plasma at 37°C for 48 hours, and aliquots were evaluated by SEC
after 1, 12, 24 and 48 hours. This indicated an overall good stability of the 64Cu-nanodiscs in
mouse plasma at body temperature. After 48 hours of incubation, a dominating peak matching
the retention time of nanodiscs could still be detected as seen in Fig 4. However, degradation
products were observed already after 1 hour of incubation and increased over time when
Fig 3. Purification of 64Cu-nanodiscs.Chromatogram obtained by size exclusion chromatography using a
Superdex 200 (10/300) column detected by UV 280 nm absorption (mAU) and radioactivity at 511 kEV
(intensity). 64Cu-nanodiscs were collected from the column at an elution time of 12.4 ml.
doi:10.1371/journal.pone.0129310.g003
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compared to the nanodisc fraction. It was not possible to determine if these smaller 64Cu-con-
taining particles were degradation products or a result of transchelation between competing
plasma proteins. The in vitro stability was judged sufficiently well for continuation of in vivo
studies. However, a further improved radiolabelling stability may be obtained by using a che-
late indicating higher in vivo stability and stronger affinity for Cu(II) than that of DOTA [27].
PET/CT-based in vivo evaluation of 64Cu labelled nanodiscs in tumor
bearing mice
Analyzed PET images (Fig 5) showed that nanodiscs were cleared from the blood in a biphasic
manner with an initial fast elimination consistent with the renal excretion followed by a much
slower clearance enhancing the tumor accumulation beyond the 12 hour time-point [28]. The
blood level dropped from 9.6% ± 1% ID/g 1 hour post injection (p.i.) to 1.3% ± 0.2% ID/g 48
hour p.i. and was significantly higher at 1 hour compared to the 12 hour, 24 hour and 48 hour
time-points (p< 0.001), whereas no significant change was seen between the 12 hour, 24 hour
and 48 hour observations. At 12 hour p.i. the blood and tumor levels were at similar levels. The
tumor accumulation increased significantly from 1 hour to 12 hour p.i. (p< 0.001) and contin-
ued to increase up to 24 hour (12 hour vs 24 hour: p = 0.08), reaching 4%ID/g and remained
steady until the end of the experiment at 48 hour p.i. (Fig 6). The steady increase in tumor
accumulation together with the stabilized blood levels from the 12 hour time-point confirmed
that the nanodiscs were circulating for a long time allowing extravasation through the leaky
tumor vasculature.
The nanodiscs were primarily cleared through renal excretion, but the liver and intestinal
uptake also reveals some excretion through the hepato-billiary route (Fig 7). Generally,
Fig 4. In vitro stability of 64Cu-nanodiscs in mouse plasma at 37°C. Chromatograms were obtained by
size exclusion chromatography (SEC) using a BioSep-SEC-s2000 column and radioactivity detected at 511
kEV. 64Cu-nanodiscs eluted from the column at approximately 6.4 ml. Analyses were carried out after 1, 12,
24 and 48 hours of incubation. Data are background subtracted and normalized by the total counts.
doi:10.1371/journal.pone.0129310.g004
Nanodiscs In Vivo
PLOSONE | DOI:10.1371/journal.pone.0129310 July 1, 2015 8 / 14
Fig 6. Biodistribution of nanodiscs from PET. The values were obtained from quantitative analysis of PET images extracted by region of interest (ROI)
image analysis of tissues of interest, n = 6. Left: liver, spleen, tumor, muscle and left ventricle (blood), right: kidney. Each type of tissue was analyzed from
PET/CT images obtained at 1, 12, 24 and 48 hours post-injection of 64Cu-nanodiscs by region of interest (ROI) image analysis. Results are presented as
percentage injected dose per grams of tissue (%ID/g).
doi:10.1371/journal.pone.0129310.g006
Fig 5. Positron emission tomography (PET)/computed tomography (CT) images of 64Cu-nanodisc distribution in tumor bearing nudemice. The
images show the coronal plane of the mouse recorded 1, 12, 24 and 48 hours post injection. The tumors are circled in white.
doi:10.1371/journal.pone.0129310.g005
Nanodiscs In Vivo
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nanoparticles and in particular nanoparticles without PEGylation suffer from recognition by
the mononuclear phagocyte system, which results in accumulation in spleen and liver. Despite
the nanodisc system being non-PEGylated, only a modest accumulation in the liver and the
spleen was observed throughout the 48 hour study period. Accumulation in muscle tissue was
low and remained steadily so throughout the experiment. For liver and muscle tissue, no signif-
icant alteration was observed throughout the 48 hour observation period, and we did not
observe splenic accumulation over time. In fact the splenic uptake was significantly lower 48
hour p.i. compared to 1 hour p.i (p = 0.031).
Following the final PET/CT scan, mice were killed, and tissues of interest were collected for
gamma-counter measurements. These results confirmed the results obtained by the quantitative
analysis of PET data. Comparing the biodistribution in the different organs, we found that the
uptake 48 hour p.i. was significantly higher in tumors compared to both blood (p< 0.001) and
muscle (p< 0.001). The pancreatic uptake was low and only slightly higher than the muscle
uptake (0.8 vs. 0.3%ID/g, p = 0.003), whereas some accumulation of the nanodiscs was observed
in the lungs at similar levels as the spleen (2.3 vs 2.0%ID/g, p = 0.173). Uptake of high density
lipoproteins (HDL) in lungs have previously been demonstrated [29] and given the resemblance
of the nanodiscs to HDL, it is not surprising that we observe this lung accumulation.
There are several possible explanations for the observed renal clearance of the nanodiscs.
Firstly, the 64Cu, observed in the kidneys, could be disassociated, if the radiochemical binding
is unstable in vivo. However, as recently demonstrated, free 64CuCl2 accumulate in liver after
the initial renal clearance to a higher degree than what we observed here [30] and 64Cu-DOTA
would also be cleared faster than what we observe [23, 31, 32]. Secondly, disassembly of the
nanodiscs in circulation would also prompt a renal clearance. HDL, which the nanodiscs
resemble, are known to disassemble in vivo upon cholesterol transport. It is possible that what we
Fig 7. Biodistribution of nanodiscs from gamma detection. Assessed by gamma counting 48 hours post
injection, n = 10. Dominating accumulation of 64Cu-nanodiscs was found in the kidneys. High accumulation
was found in liver and tumor tissue as well.
doi:10.1371/journal.pone.0129310.g007
Nanodiscs In Vivo
PLOSONE | DOI:10.1371/journal.pone.0129310 July 1, 2015 10 / 14
see in the kidneys is 64Cu-labeled MSP disassociated from the phospholipid part of the nanodisc.
However, we would have expected faster clearance of disassembled particles [33]. Therefore, we
believe that the renal clearance rate is a matter of size and shape. The maximal dimension of
the nanodiscs is approximately 130 Å, which is close to the cutoff for renal clearance of approxi-
mately 100 Å [34]. However, since the particles have the shape of approximately 50 Å thick ellip-
soidal discs, it appears likely and consistent with the PET data that the nanodiscs can penetrate
the kidney barriers enabling renal excretion of intact 64Cu-DOTA-nanodiscs.
It has been argued that 64Cu-DOTA is unstable in vivo prompting the evaluation of alterna-
tive chelates. However, chelates such as CB-TE2A do not seem to be superior to 64Cu-DOTA
and requires much more harsh reaction conditions, which are unfavorable for protein labeling
[31, 32]. We also believe that our in vivo data confirm sufficient in vivo stability due to the long
blood circulation time and tumor accumulation up to 48h p.i.
The observed renal clearance is potentially of great importance for future clinical applica-
tions, as it represents a compromise between long blood circulation and ability for clearance
from the body, thereby avoiding harmful accumulation in the body of potentially toxic prod-
ucts, if e.g. inorganic materials were to be carried with the nanodiscs[34]. However, the balance
between renal and hepato-biliary clearance should be easily tunable through PEGylation of
either the MSP or the lipids in the disc [35].
Conclusion
With this study, we have provided new information on the biodistribution of nanodiscs, of cen-
tral importance for future diagnostic and therapeutic applications and revealed a pattern which
is very different from that observed from other well-known nanoparticles. Liposomes, which
have been widely used as drug carriers [36], are found to accumulate to a high degree in liver
and spleen apart from accumulation in tumor tissue [37]. Interestingly, this distribution pat-
tern differs to a great extend from that observed for nanodiscs, which abundantly accumulates
in the kidneys. Liver accumulation was observed for the nanodiscs as well but to a considerably
lower degree. Hence, nanodiscs may be applied in cases, where a low liver accumulation is
required. The low accumulation of nanodiscs in the spleen is also worth emphasizing, as this
indicates a low immunogenicity of the nanodiscs evaluated. This is a general problem for sev-
eral other nanoparticles and in particular for polymer based systems [38].
In conclusion, we have for the first time determined the biodistribution of nanodiscs in vivo.
A simple and easy method for 64Cu radiolabelling of protein-based biomolecules that can be
used for biodistribution studies by PET imaging was developed. We have characterized the
DOTA-conjugated nanodiscs by SANS and SAXS and evaluated their biodistribution in tumor
bearing mice in order to elucidate their potential for medical use. We find that the nanodisc
particles penetrate very well into tumor tissue making them good candidates for drug delivery
systems as well as imaging agents.
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